Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Malignant Melanoma

  Free Subscription


Articles published in Cancer

Retrieve available abstracts of 46 articles:
HTML format



Single Articles


    June 2024
  1. CZARNECKA AM, Ostaszewski K, Blonski PJ, Szumera-Cieckiewicz A, et al
    Long-term efficacy of neoadjuvant-adjuvant targeted therapy in borderline resectable stage IIIB-D and IV melanoma.
    Cancer. 2024 Jun 6. doi: 10.1002/cncr.35425.
    PubMed     Abstract available


    April 2024
  2. KHATTAK MA, Luke JJ
    Top advances of the year: Melanoma.
    Cancer. 2024 Apr 29. doi: 10.1002/cncr.35354.
    PubMed    


    March 2024
  3. ROSENBERG SM, McCue S, He J, Lafky JM, et al
    Alliance A151945: Accrual and characteristics of adolescent and young adult patients in Alliance trials from 2000 to 2017.
    Cancer. 2024;130:750-769.
    PubMed     Abstract available


    January 2024
  4. VAN NOT OJ, van den Eertwegh AJM, Haanen JB, van Rijn RS, et al
    BRAF/MEK inhibitor rechallenge in advanced melanoma patients.
    Cancer. 2024 Jan 10. doi: 10.1002/cncr.35178.
    PubMed     Abstract available


    October 2023
  5. NIERENGARTEN MB
    First person profile: Jedd Wolchok, MD: Advances in treating metastatic melanoma can, in part, be charted by the career of Dr Wolchok, who was on the front lines of investigating immunotherapy science and developed the first immunologic agents to trea
    Cancer. 2023;129:3190-3191.
    PubMed    


    September 2023
  6. EROGLU Z, Chen YA, Smalley I, Li J, et al
    Combined BRAF, MEK, and heat-shock protein 90 (HSP90) inhibition in advanced BRAF V600-mutant melanoma.
    Cancer. 2023 Sep 30. doi: 10.1002/cncr.35029.
    PubMed     Abstract available


    July 2023
  7. MOORADIAN MJ, Sullivan RJ
    The case for adjuvant BRAF-targeted therapy versus adjuvant anti-PD-1 therapy for patients with resected, high-risk melanoma.
    Cancer. 2023;129:2117-2121.
    PubMed     Abstract available


  8. NIERENGARTEN MB
    Neoadjuvant immunotherapy improves outlook in high-risk melanoma.
    Cancer. 2023;129:1952.
    PubMed    


    June 2023
  9. DEMKOWICZ P, Pointdujour-Lim R, Miguez S, Lee Y, et al
    Determinants of overall survival in patients with metastatic uveal melanoma.
    Cancer. 2023 Jun 29. doi: 10.1002/cncr.34927.
    PubMed     Abstract available


  10. MOORADIAN MJ, Cleary JM, Giobbie-Hurder A, Darville LNF, et al
    Dose-escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF-mutant solid tumors.
    Cancer. 2023;129:1904-1918.
    PubMed     Abstract available


    May 2023
  11. PATUZZO R, Mattavelli I, Gallino G, Galeone C, et al
    The prognostic role of mitotic rate in cutaneous malignant melanoma: Evidence from a multicenter study on behalf of the Italian Melanoma Intergroup.
    Cancer. 2023 May 10. doi: 10.1002/cncr.34824.
    PubMed     Abstract available


  12. GERSHENWALD JE
    Mitotic rate in primary cutaneous melanoma: Cell division matters.
    Cancer. 2023 May 10. doi: 10.1002/cncr.34825.
    PubMed    


    April 2023
  13. GALUS L, Michalak M, Lorenz M, Stoinska-Swiniarek R, et al
    Vitamin D supplementation increases objective response rate and prolongs progression-free time in patients with advanced melanoma undergoing anti-PD1 therapy.
    Cancer. 2023 Apr 24. doi: 10.1002/cncr.34718.
    PubMed     Abstract available


    March 2023
  14. LEV-ARI S, Serzan M, Wu T, Ip A, et al
    The impact of immunosuppressive agents on immune checkpoint inhibitor efficacy in patients with advanced melanoma: A real-world, multicenter, retrospective study.
    Cancer. 2023 Mar 23. doi: 10.1002/cncr.34742.
    PubMed     Abstract available


  15. EROGLU Z, Krinshpun S, Kalashnikova E, Sudhaman S, et al
    Circulating tumor DNA-based molecular residual disease detection for treatment monitoring in advanced melanoma patients.
    Cancer. 2023 Mar 4. doi: 10.1002/cncr.34716.
    PubMed     Abstract available


    January 2023
  16. KLEIN O, Kee D, Nagrial A, Markman B, et al
    Is there a role for combined anti-PD-1/CTLA-4 checkpoint blockade in the management of advanced biliary tract cancers?
    Cancer. 2023 Jan 24. doi: 10.1002/cncr.34660.
    PubMed    


  17. SAHAI V, Zalupski MM
    Reply to "Is there a role for combined anti-PD-1/CTLA-4 checkpoint blockade in the management of advanced biliary tract cancers?".
    Cancer. 2023 Jan 24. doi: 10.1002/cncr.34659.
    PubMed    


  18. WIN TS, Tsao H
    Keratinocytic skin cancers-Update on the molecular biology.
    Cancer. 2023 Jan 16. doi: 10.1002/cncr.34635.
    PubMed     Abstract available


  19. AUGUSTIN RC, Luke JJ
    Top advances of the year: Melanoma.
    Cancer. 2023 Jan 11. doi: 10.1002/cncr.34590.
    PubMed    


    December 2022
  20. CRONIN KA, Scott S, Firth AU, Sung H, et al
    Annual report to the nation on the status of cancer, part 1: National cancer statistics.
    Cancer. 2022;128:4251-4284.
    PubMed     Abstract available


    November 2022
  21. EGUCHI MM, Elder DE, Barnhill RL, Piepkorn MW, et al
    Prognostic modeling of cutaneous melanoma stage I patients using cancer registry data identifies subsets with very-low melanoma mortality.
    Cancer. 2022 Nov 7. doi: 10.1002/cncr.34490.
    PubMed     Abstract available


    September 2022
  22. SONDAK VK, Neves RI, Wuthrick EJ, Messina JL, et al
    Current and future approaches in the surgical management of T3b/T4 primary and locoregionally advanced melanoma.
    Cancer. 2022 Sep 6. doi: 10.1002/cncr.34449.
    PubMed     Abstract available


    August 2022
  23. JOHANNET P, Simons M, Qian Y, Azmy N, et al
    Risk and tropism of central nervous system (CNS) metastases in patients with stage II and III cutaneous melanoma.
    Cancer. 2022 Aug 25. doi: 10.1002/cncr.34435.
    PubMed     Abstract available


    May 2022
  24. O'ROURKE K
    Relatlimab plus nivolumab beneficial for previously untreated metastatic or unresectable melanoma.
    Cancer. 2022;128:1887.
    PubMed    


    April 2022
  25. BRUIJNEN CP, Koldenhof JJ, Verheijden RJ, van den Bos F, et al
    Frailty and checkpoint inhibitor toxicity in older patients with melanoma.
    Cancer. 2022 Apr 19. doi: 10.1002/cncr.34230.
    PubMed     Abstract available


  26. O'ROURKE K
    Late-day immunotherapy infusions may affect overall survival in patients with melanoma.
    Cancer. 2022;128:1358.
    PubMed    


    March 2022
  27. KARAPETYAN L, Yang X, Knight AD, Huang Z, et al
    Poorer survival outcomes in patients with multiple versus single primary melanoma.
    Cancer. 2022 Mar 23. doi: 10.1002/cncr.34169.
    PubMed     Abstract available


  28. O'ROURKE K
    Study shows that patients older than 80 years benefit from immunotherapy.
    Cancer. 2022;128:1155-1156.
    PubMed    


    February 2022
  29. LEE KE, Bender DA, Koutcher LD, Hyde B, et al
    Risk of corticosteroid treatment and hospitalization after checkpoint inhibitor and radiation therapy in patients with cancer.
    Cancer. 2022;128:819-827.
    PubMed     Abstract available


  30. MORRISON SL, Han G, Elenwa F, Vetto JT, et al
    Is the presence of tumor-infiltrating lymphocytes predictive of outcomes in patients with melanoma?
    Cancer. 2022 Feb 1. doi: 10.1002/cncr.34013.
    PubMed     Abstract available


    November 2021
  31. PATEL AB, Farooq S, Welborn M, Amaria RN, et al
    Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti-CTLA4 and anti-PD1 combination immunotherapy: Incidence, management, and clinical benefit.
    Cancer. 2021 Nov 1. doi: 10.1002/cncr.34004.
    PubMed     Abstract available


    July 2021
  32. MACARTHUR KM, Baumann BC, Sobanko JF, Etzkorn JR, et al
    Compliance with sentinel lymph node biopsy guidelines for invasive melanomas treated with Mohs micrographic surgery.
    Cancer. 2021 Jul 22. doi: 10.1002/cncr.33651.
    PubMed     Abstract available


  33. SONDAK VK, Messina JL
    What's new in pediatric melanoma and Spitz tumors? Pretty much everything.
    Cancer. 2021 Jul 6. doi: 10.1002/cncr.33749.
    PubMed     Abstract available


    May 2021
  34. PRINTZ C
    Cutaneous Melanoma Overdiagnosed, Researchers Find.
    Cancer. 2021;127:1547.
    PubMed    


  35. TAYLOR LA, Eguchi MM, Reisch LM, Radick AC, et al
    Histopathologic synoptic reporting of invasive melanoma: How reliable are the data?
    Cancer. 2021 May 4. doi: 10.1002/cncr.33612.
    PubMed     Abstract available


  36. PRINTZ C
    First Person Profile: Cheryl Willman, MD: As director and CEO of the University of New Mexico Comprehensive Cancer Center, Dr. Willman has led major health equity initiatives while making pioneering discoveries in precision medicine.
    Cancer. 2021;127:1357-1358.
    PubMed    


    April 2021
  37. GOGEBAKAN KC, Mukherjee K, Berry EG, Sonmez K, et al
    Impact of novel systemic therapies on the first-year costs of care for melanoma among Medicare beneficiaries.
    Cancer. 2021 Apr 27. doi: 10.1002/cncr.33515.
    PubMed     Abstract available


  38. ESKANDER A, Marqueen KE, Edwards HA, Joshua AM, et al
    To ban or not to ban tanning bed use for minors: A cost-effectiveness analysis from multiple US perspectives for invasive melanoma.
    Cancer. 2021 Apr 12. doi: 10.1002/cncr.33499.
    PubMed     Abstract available


  39. BROMAN KK, Hughes T, Dossett L, Sun J, et al
    Active surveillance of patients who have sentinel node positive melanoma: An international, multi-institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy trial II (MSLT-2).
    Cancer. 2021 Apr 7. doi: 10.1002/cncr.33483.
    PubMed     Abstract available


  40. GERSHENWALD JE
    Active surveillance of patients who have melanoma with a positive sentinel node in an era of effective adjuvant therapy: Early lessons learned ... and still learning.
    Cancer. 2021 Apr 7. doi: 10.1002/cncr.33484.
    PubMed    


    March 2021
  41. KEMPF E, Zalcman G, Lebbe C
    National early access programs and clinical trials: What opportunities for early access to therapeutic innovations for patients with malignant melanoma?
    Cancer. 2021 Mar 31. doi: 10.1002/cncr.33495.
    PubMed    


  42. CHRISTEN C, Belgodere L, Guillot B, Jumeau C, et al
    Access to innovation through the national early access program and clinical trials for patients with malignant melanoma.
    Cancer. 2021 Mar 25. doi: 10.1002/cncr.33492.
    PubMed     Abstract available


  43. BANDER ED, Yuan M, Carnevale JA, Reiner AS, et al
    Melanoma brain metastasis presentation, treatment, and outcomes in the age of targeted and immunotherapies.
    Cancer. 2021 Mar 2. doi: 10.1002/cncr.33459.
    PubMed     Abstract available


    November 2020
  44. KARAPETYAN L, Yang X, Wang H, Sander CA, et al
    Indoor tanning exposure in association with multiple primary melanoma.
    Cancer. 2020 Nov 10. doi: 10.1002/cncr.33307.
    PubMed     Abstract available


    September 2020
  45. LI M, Sack JS, Rahma OE, Hodi FS, et al
    Outcomes after resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis.
    Cancer. 2020 Sep 5. doi: 10.1002/cncr.33165.
    PubMed     Abstract available


    May 2020
  46. ARORA M, Chen Y, Hageman L, Wu J, et al
    Morbidity burden in survivors of multiple myeloma who underwent autologous transplantation: A Bone Marrow Transplantation Survivor Study.
    Cancer. 2020 May 15. doi: 10.1002/cncr.32941.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.